Supplemental: Genetic testing

Genetic screening included, for patients 1 to 4:

ABCC9; ACTA1; ACTC1; ACTN2; ANKRD1; BAG3; CAVIN4; CDH2; CRYAB; CSRP3; CTF1; CTNNA3; DES; DMD; DMPK; DOLK; DSC2; DSG2; DSP; EMD; EPG5; EYA4; FHL1; FHL2; FKTN; FLNC; GATAD1; GLA; HAMP; HFE; HFE2 (HJV); IDH2; ILK; JUP; LAMA4; LAMP2; LDB3; LMNA ; MPO; MYBPC3; MYH6; MYH7; MYL2; MYL3; MYPN; NEBL; NEXN; NKX2-5; PDLIM3; PKP2; PLN; PRDM16; PRKAG2; PSEN1; PSEN2; RAB3;GAP2; RAF1; RBM20; RYR2; SCN1B; SCN5A; SDHA; SGCB; SGCD; SLC40A1; SYNE1; SYNE2; TAZ; TBX20; TCAP; TFR2; TGFB3; TMEM43; TMPO; TNNC1; TNNI3; TNNI3K; TNNT2; TPM1; TTN; TTR; TXNRD2; VCL; XK.

In patient 3, the hypertrophic cardiomyopathy (HCM) panel was also added as part of our broader cardiomyopathy panel in the setting of an aborted cardiac arrest, including (as extra genes to those already reported above): TRIM63; CAV3; MURC; MYLK2; MYOZ2; JPH2; CALR3; KLF10; MYO6; CACNA1C.

Finally, in patients 5, genetic screening included HCM, laminopathy genes and aortic disorder-related genes:

ACTA2; BGN; COL3A1; FBN1; FLNA; FOXE3; LOX; MAT2A; MFAP5; MYH11; MYLK; PRKG1; SKI; SMAD3; TGFB2; TGFB3; TGFBR1; TGFBR2; SLC2A10; ABCC9; ACADVL; ACTC1; ACTN2; AGL; ATAD3A; BAG3; BRAF; CACNA1C; CALR3; CAV3; COX15; CRYAB; CSRP3; DES; FHL1; FHOD3; FLNC; FXN; GAA; GLA; GYG1; HRAS; JPH2; KLF10; LAMP2; LDB3; LZTR1; MAP2K1; MAP2K2; MYBPC3; MYH6; MYH7; MYL2; MYL3; MYLK2; MYO6; MYOZ2; MYPN; NEXN; NRAS; PLN; PRKAG2; PTPN11; RAF1; RIT1; SHOC2; SLC25A4; SOS1; TCAP; TNNC1; TNNI3; TNNT2; TPM1; TRIM63; TTN; TTR; VCL; CDH2; CTNNA3; DSC2; DSG2; DSP; DTNA; EMD; FHL1; JUP; LAMA4; LDB3; LMNA; MIB1; MYH7B; PKP2; PRDM16; RYR2; SYNE1; SYNE2; TGFB3; TMEM43; TOR1AIP1.

Additionally, MLPA on the LMNA gene was performed on all patients.